期刊文献+

大鼠肾移植后抗波形蛋白抗体升高与慢性移植肾肾病的相关性 被引量:1

Antivimentin antibody in rats with chronic allograft nephropathy
原文传递
导出
摘要 目的研究大鼠肾移植术后抗波形蛋白抗体的表达水平与慢性移植肾肾病(CAN)的相关性,以及不同免疫抑制剂对其的影响。方法选取近交系F344大鼠作为同系肾移植的供、受者(共9对),选取F344和Lewis大鼠分别作为同种肾移植的供、受者(共27对)。同系移植组受者术后不给予免疫抑制剂;同种移植组受者术后10d内给予环孢素A(CsA),然后将同种移植组受者随机平均分为生理盐水(NS)组、CsA组和霉酚酸酯(MMF)组(每组9只),分别给予NS、CsA和MMF灌胃。术后第4、8和12周时分别处死每组受者3只,观察CAN的进展、波形蛋白及其基因的表达以及抗波形蛋白抗体的水平,取正常大鼠(包括F344和Lewis大鼠)作为对照。结果观察期内同系移植组未发生CAN;而同种移植组发生了CAN,且不断加重,其中CsA组和NS组的CAN病理改变非常明显,而MMF组明显较轻。术前所有受者血清中均未检测到抗波形蛋白IgM和IgG抗体,术后也未检测到抗波形蛋白IgM抗体;术后同系移植组仅检测到微量的抗波形蛋白IgG抗体,同种移植组检测到大量的抗波形蛋白IgG抗体。随着CAN的进展,同种移植中,CsA组和NS组血清抗波形蛋白IgG抗体的水平逐渐增高,而MMF组抗体水平的增高显著低于NS组(P〈0.05),但仍显著高于同系移植组(P〈0.05)。结论大鼠同种肾移植术后,受者体内可产生抗波形蛋白IgG抗体,且产生的时间早于CAN,抗波形蛋白IgG抗体水平也会随着CAN的进展而增高。MMF可抑制抗波形蛋白IgG抗体的产生,CsA无此作用。 Objective To investigate the expression of antivimentin in rats after renal transplantion, its relationship with chronic allograft nephropathy (CAN) and the curative effectiveness of different imrnunosuppressants. Methods Renal transplantation was performed by using F344 rats as both donors and recipients in isograft group. F344 and Lewis rats were used as donors and recipients respectively in allograft group. Allograft recipients were first treated with cyclosporine A (CsA, 10 mg.kg^-1·day^-1 for 10 days) and then divided into 3 groups (each n = 9) : vehicle group, CsA (6 mg.kg^-1·day^-1)-treated group and mycophenolate (MMF) (20 mg.kg^-1·day^-1)-treated group. Blood was taken before and at 4th, 8th and 12th week after operation. The rats were sacrificed and the renal iso- and allografts were harvested. The serum creatinine was determined, and pathological changes were analyzed according to Banff 97 criteria. The levels of vimentin were detected and localized by quantitative RT-PCR and immunohistochemistry, and the levels of vimentin antibodies (IgM, IgG) were analyzed by using ELISA. Results Both antivimentin IgM and IgG were not found in the sera of all recipient rats before transplantation, and no IgM was found in the sera of all recipient rats after transplantation. A trace of antivimentin IgG was detected in the sera of rats receiving isografts while IgG was evident in the rats receiving allografts. At 4th week, CAN was not obvious in 3 allograft groups. The IgG levels in vehicle, CsA-treated and MMF-treated groups were 0. 173 ± 0. 016, 0. 174±0. 026 and 0. 141 ± 0. 007, respectively (P〉0. 05). Along with progression of CAN (Banff Score 5.33± 0. 58 and 12. 57± 1.16 in vehicle group at 8th and 12th week, respectively,P = 0. 001), the levels of IgG in vehicle group was increased gradually (0. 235± 0. 014, 0. 285± 0. 019, at 8 th, 12 th week, P = 0. 009 ). CsA did not prevent the formation of IgG ( 0. 233 ± 0. 020 , 0. 274 ±0. 029) and the progression of CAN (4. 67 ± 1.53, 13. 33 ± 1.53) at 8th, 12th week. Meanwhile, MMF could significantly decrease the formation of IgG and the progression of CAN. Conclusions The antivimentin antibody (IgG) is produced in the rats with renal allografts. The formation of antivimentin antibody is earlier than the development of CAN and its levels are increased along with the progression of CAN. MMF can suppress the production of antivimentin antibody, while CsA has no this effect.
出处 《中华器官移植杂志》 CAS CSCD 北大核心 2008年第12期737-740,共4页 Chinese Journal of Organ Transplantation
基金 基金项目:国家自然科学基金(2003CB515504) 国家教育部博士基金(JYB00402051025)
关键词 肾移植 波形蛋白 大鼠 Kidney transplantation Vimentin Rats
  • 相关文献

参考文献17

  • 1Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol, 1999, 10(1):167-181.
  • 2Colvin RB. Chronic allograft nephropathy. N Engl J Med, 2003, 349(24) : 2288-2290.
  • 3Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol, 2003, 25 (2) : 119-140.
  • 4Terasaki PI. Humoral theory of transplantation. Am J Transplant, 2003, 3(6): 665-673.
  • 5Sumitran-Holgersson S, Holgersson J. Clinical importance of non- HLA antibodies in solid organ transplantation. Current opinion in organ transplantation, 2006, 11(4):425-432.
  • 6Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation, 2001, 71 (7) : 886-892.
  • 7Kamada N. A description of cuff techniques for renal transplantation in the rat. Use in studies of tolerance induction during combined liver grafting. Transplantation, 1985, 39 (1) :93-95.
  • 8Yiping Lu, Yupeng Xin, Rui Gao. The explorative study of the mechanism and drug intervention of chronic allograft nephropathy induced by Isehemia Reperfusion. Transplantation, 2004, 78 suppl 2:S741.
  • 9Goto H, Yasui Y, Kawajiri A, et al. Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation in the cytokinetic process. J Biol Chem, 2003, 278(10):8526-2530.
  • 10Bravo J, Quiroz Y, Pons H, et al. Vimentin and heat shock protein expression are induced in the kidney by angiotensin and by nitric oxide inhibition. Kidney Int,2003 Suppl, (86):S46- 51.

同被引文献29

  • 1Porcheray F, DeVito J, Yeap BY,et al. Chronic humoral rejection of human kidney allografts associates with broad autoantibody re- sponses [ J ]. Transplantation, 2010,89 (10) : 1239-1246.
  • 2Win TS, Rehakova S, Negus MC,et al. Donor CIM T cells con- tribute to cardiac allograft vasculopathy by providing help for au- toantibody production [ J ]. Cite Heart Fail, 2009, 2 ( 4 ) : 361-369.
  • 3Goers TA, Ramachandran S, Aloush A,et al. De novo production of K-alphal tubulin-specifie antibodies: role in chronic lung al- lograft rejection [ J]. J Immurtol, 2008,180 (7) : 4487-4494.
  • 4Miyagawa-Hayashino A, Haga H, Egawa H,et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation [ J~. Transplantation, 2004,78( 1 ) : 128-135.
  • 5Dieterle CD, Hierl FX, Gutt B, et al. Insulin and islet autoanti- bodies after pancreas transplantation [ J]. Transpl Int, 2005,18 (12) :1361-1365.
  • 6Azimzadeh AM, Pfeiffer S, Wu GS, et al. Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates [ J ~. Am J Transplant, 2005,5 (10) : 2349-2359.
  • 7Tanaka M, Zwie~choniewska M, Mokhtari GK,et al. Progression of alloresponse and tissue-specific immunity during graft coronary artery disease [-JT. Am J Transplant, 2005.5(6) : 1286-1296.
  • 8Birnbaum LM, Lipman M, Paraskevas S, et al. Management of chronic allograft nephropathy : a systematic review [ J 1. Clin J Am Soc Nephrol, 2009,4(4) : 860-865.
  • 9Snell GI, Westall GP. The contribution of airway ischemia and vascular remodelling to the pathophysiology of bronchiolitis oblite- rans syndrome and chronic lung allograft dysfunction [ J ]. Curr Opin Organ Transplant, 2010,15 (5) : 558-562.
  • 10Shilling RA, Wilkes DS. Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond [ J]. Am J Transplant, 2009,9(8) : 1714-1718.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部